81 completed, 68 active not recruiting, 51 recruiting, 29 terminated. 161 Phase 2, 68 Phase 1, 42 Phase 3, 6 Early Phase 1, 1 Not applicable.
Follow Disulfides: new trials by email Literature Review of Disulfides trials Research Report on Disulfides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-12-10 | 2026-06-10 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-05-12 |
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-09-17 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older Anakinra, Biospecimen Collection, Computed Tomography - Melanoma | Phase 1 | Not yet recruiting | University of Southern California | 40 | 2026-11-01 | 2026-09-24 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection - Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 87 | 2026-09-24 | 2026-10-20 |
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 46 | 2026-05-29 | 2026-08-20 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-22 |
| Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer Celecoxib, Durvalumab, Tremelimumab - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Emory University | 39 | 2026-01-02 | 2026-01-28 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma all-trans retinoic acid, Cemiplimab, Computed Tomography - Leiomyosarcoma, Sarcoma | Phase 2 | Recruiting | Gabriel Tinoco | 16 | 2025-09-10 | 2026-10-01 |
| Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer Biospecimen Collection, Ceralasertib, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 630 | 2025-08-07 | 2026-09-21 |
| External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer Bevacizumab, Biospecimen Collection, Brachytherapy - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 35 | 2025-07-29 | 2026-08-12 |
Showing 20 of 249. Sign in to see all of them.
Lung Neoplasms (28) · Ovarian Neoplasms (27) · Fallopian Tube Neoplasms (24) · Carcinoma, Non-Small-Cell Lung (21) · Colorectal Neoplasms (17) · Glioblastoma (11) · Melanoma (11) · Pancreatic Neoplasms (11) · Carcinoma, Hepatocellular (10) · Carcinoma, Renal Cell (10) · Breast Neoplasms (9) · Lymphoma, Large B-Cell, Diffuse (8) · Squamous Cell Carcinoma of Head and Neck (8) · Brenner Tumor (7) · Colonic Neoplasms (7)
National Cancer Institute (NCI) (96) · M.D. Anderson Cancer Center (37) · Mayo Clinic (13) · University of Washington (13) · City of Hope Medical Center (12) · Academic and Community Cancer Research United (7) · Jonsson Comprehensive Cancer Center (7) · Roswell Park Cancer Institute (7) · SWOG Cancer Research Network (7) · Emory University (6) · OHSU Knight Cancer Institute (6) · Northwestern University (5) · Fred Hutchinson Cancer Center (3) · NRG Oncology (3) · ECOG-ACRIN Cancer Research Group (2)
United States (243) · Canada (25) · Puerto Rico (11) · Australia (4) · Peru (4) · South Africa (4) · Japan (3) · South Korea (3) · Guam (2) · Hong Kong (2) · New Zealand (2) · Ireland (1) · Israel (1) · Mexico (1) · Singapore (1)
Emese Zsiros (4) · Vassiliki Papadimitrakopoulou (3) · Amir A Jazaeri (2) · Hope S Rugo (2) · Jing Zeng (2) · Mark Gilbert (2) · Michael Schweizer (2) · Nilofer S Azad (2) · Yinghong Wang (2) · A P Chen (1) · Aaron S Mansfield (1) · Aarti Bhatia (1) · Adam S Levy (1) · Adel Kardosh (1) · Afshin Dowlati (1)
PMID 37185961, PMID 32379297, PMID 34616010, PMID 35175355, PMID 21941283, PMID 21997132, PMID 22178121, PMID 22204724, PMID 23219660, PMID 23233715, PMID 23620404, PMID 24047116, PMID 24552317, PMID 24552320, PMID 24817603, PMID 25092775, PMID 25318437, PMID 25488966, PMID 25638326, PMID 25713428, PMID 25847373, PMID 25926352, PMID 26056183, PMID 26077237, PMID 26410619, PMID 26487588, PMID 26576593, PMID 26586415, PMID 26933849, PMID 27138575, PMID 27217446, PMID 28006055, PMID 28384065, PMID 28438473, PMID 28620884, PMID 28646344, PMID 28756902, PMID 29129443, PMID 29169877, PMID 29550184, PMID 29789969, PMID 30040523, PMID 30054636, PMID 31002578, PMID 31216226, PMID 31268130, PMID 31276981, PMID 31393548, PMID 31513481, PMID 31618129
U10CA180868 (29), U10CA180820 (18), U10CA027469 (13), P30CA033572 (12), U10CA180888 (12), U10CA180821 (10), P30CA015083 (9), U10CA021115 (7), U10CA021661 (7), P30CA060553 (6), P30CA138292 (6), U10CA031946 (6), P30CA015704 (4), P30CA016672 (4), U10CA032102 (4)